The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 06, 2021

Filed:

Feb. 06, 2017
Applicant:

Washington University, St. Louis, MO (US);

Inventors:

Alexander Sasha Krupnick, St. Louis, MO (US);

Daved Henry Fremont, St. Louis, MO (US);

Eric Reed Lazear, St. Louis, MO (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/55 (2006.01); C07K 14/52 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01); C07K 14/54 (2006.01); C07K 14/545 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 14/55 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 14/52 (2013.01); C07K 14/545 (2013.01); C07K 14/5418 (2013.01); C07K 14/5443 (2013.01); C07K 14/70596 (2013.01); C07K 16/2851 (2013.01); A61K 38/00 (2013.01);
Abstract

The present disclosure encompasses compositions and methods for targeted cytokine delivery. The compositions disclosed herein comprise a cytokine linked to an NKG2D ligand or PD1 ligand and may improve immunotherapy by limiting side effects associated with immunotherapy. The present disclosure also encompasses compositions and methods for recruiting cytotoxic lymphocytes to target cells using NKG2D receptor ligands or PD1 ligands. The compositions disclosed herein comprise a NKG2D receptor ligand and a targeting molecule and may improve immunotherapy by limiting side effects associated with immunotherapy.


Find Patent Forward Citations

Loading…